Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

(2017) Olivier Lortholary et al.   LANCET

Combenefit: an interactive platform for the analysis and visualization of drug combinations

(2016) Giovanni Y. Di Veroli et al.   BIOINFORMATICS

Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

(2016) Yuan Wang et al.   Drug Design Development and Therapy

Masitinib for gastrointestinal stromal tumors

(2016) Mehdi Brahmi et al.   Expert Opinion on Orphan Drugs

Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors

(2015) Oliver Hantschel   ACS Chemical Biology

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

(2015) G. Deplanque et al.   ANNALS OF ONCOLOGY

Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication

(2014) David A. Nathanson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Small molecule SIRT1 activators for the treatment of aging and age-related diseases

(2014) Basil P. Hubbard et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Development of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission Tomography

(2013) Jennifer M. Murphy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structural characterization of new deoxycytidine kinase inhibitors rationalizes the affinity-determining moieties of the molecules

(2013) Julian Nomme et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma

(2012) Raphaël Maréchal et al.   GASTROENTEROLOGY

Viral immune modulators perturb the human molecular network by common and unique strategies

(2012) Andreas Pichlmair et al.   NATURE

Post-Translational Phosphorylation of Serine 74 of Human Deoxycytidine Kinase Favors the Enzyme Adopting the Open Conformation Making It Competent for Nucleoside Binding and Release

(2011) Saugata Hazra et al.   BIOCHEMISTRY

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

(2011) Jean-Philippe Spano et al.   INVESTIGATIONAL NEW DRUGS

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

(2011) Hedy L Kindler et al.   LANCET ONCOLOGY

Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast?

(2011) Ranran Zhang et al.   LEUKEMIA & LYMPHOMA

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

(2011) Theonie Anastassiadis et al.   NATURE BIOTECHNOLOGY

XDS

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors

(2010) Kevin A. Hahn et al.   AMERICAN JOURNAL OF VETERINARY RESEARCH

Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase

(2010) Jennifer Sigmond et al.   ANTI-CANCER DRUGS

Turning enzymes ON with small molecules

(2010) Julie A Zorn et al.   Nature Chemical Biology

Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant

(2010) Samantha Perez-Miller et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model

(2010) Martine Humbert et al.   PLoS One

Resistance to Imatinib: Mutations and Beyond

(2010) Paul La Rosée et al.   SEMINARS IN HEMATOLOGY

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

(2009) Patrice Dubreuil et al.   PLoS One

Small-Molecule Activators of a Proenzyme

(2009) D. W. Wolan et al.   SCIENCE

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

(2008) T. Qin et al.   BLOOD

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY